ERBB2 and breast cancer: Thus, this study aimed to investigate the correlation of GDF-15 levels with clinical features, biochemical indices, and especially its predictive value for the risk of cardiotoxicity in HER2-positive breast cancer patients receiving neoadjuvant dual anti-HER2 therapy.